20200527 TG AGM 2020
Category: Press release
Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
20200515 BT-001_AACR curtain raiser EN
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
20200515_AACR myvac curtain raiser EN
Transgene reports Q1 2020 financial position and business update
20200506 TG FINANCIAL T1- US
Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
20200504 – TG Vaxxell EN
Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
20200402PR-EN availability URD 2019
Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
20200403 – availability doc AG – EN
Major R&D milestones achieved in 2019 and strong clinical activity in 2020
20200311 Resultats 2019 EN
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
20200303 BT-001 presentations EN
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
20200220 PR FPI 6002.03 EN